Stephanie J Lee

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. doi request reprint Individual physician practice variation in hematopoietic cell transplantation
    Stephanie J Lee
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D5 290, Seattle, WA 98109, USA
    J Clin Oncol 26:2162-70. 2008
  2. ncbi request reprint Optimistic expectations and survival after hematopoietic stem cell transplantation
    Stephanie J Lee
    Department of Medical Oncology, and Center for Outcomes and Policy Research, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Biol Blood Marrow Transplant 9:389-96. 2003
  3. ncbi request reprint Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia
    Jennifer R Brown
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Biol Blood Marrow Transplant 12:1056-64. 2006
  4. ncbi request reprint Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial
    Stephanie J Lee
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 104:1559-64. 2004
  5. ncbi request reprint Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation
    Corey Cutler
    Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Biol Blood Marrow Transplant 10:328-36. 2004
  6. ncbi request reprint Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation
    Corey Cutler
    Department of Medical Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 11:551-7. 2005
  7. pmc Costs of allogeneic hematopoietic cell transplantation with high-dose regimens
    Akiko M Saito
    Division of Medical Oncology, Dana Farber Cancer Institute, and Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Biol Blood Marrow Transplant 14:197-207. 2008
  8. ncbi request reprint Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age
    Edwin P Alyea
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Blood 105:1810-4. 2005
  9. ncbi request reprint Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens
    Corey Cutler
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 11:383-8. 2005
  10. ncbi request reprint Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
    Vincent T Ho
    Dana Farber Cancer Institute, 44 Binney St, D1B21, Boston, MA 02115, USA
    Blood 104:1224-6. 2004

Detail Information

Publications65

  1. doi request reprint Individual physician practice variation in hematopoietic cell transplantation
    Stephanie J Lee
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D5 290, Seattle, WA 98109, USA
    J Clin Oncol 26:2162-70. 2008
    ..Previous studies have evaluated practice variation in hematopoietic cell transplantation (HCT) among transplant centers and countries. There are no studies investigating individual physician practice variation in HCT...
  2. ncbi request reprint Optimistic expectations and survival after hematopoietic stem cell transplantation
    Stephanie J Lee
    Department of Medical Oncology, and Center for Outcomes and Policy Research, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Biol Blood Marrow Transplant 9:389-96. 2003
    ..Our data suggest an association between more optimistic expectations and early survival following hematopoietic stem cell transplantation, but this association is not present by 6 months posttransplantation...
  3. ncbi request reprint Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia
    Jennifer R Brown
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Biol Blood Marrow Transplant 12:1056-64. 2006
    ....
  4. ncbi request reprint Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial
    Stephanie J Lee
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 104:1559-64. 2004
    ..002). Both relapse- and GVHD-related mortality contributed to the increased mortality in the combination group. The combination of corticosteroids and daclizumab should not be used as initial therapy of acute GVHD...
  5. ncbi request reprint Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation
    Corey Cutler
    Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Biol Blood Marrow Transplant 10:328-36. 2004
    ..Mucositis was modest, engraftment was prompt, and transplant-related toxicity was modest. Methotrexate-free, sirolimus-based GVHD prophylactic regimens should be tested in randomized trials against the current standard of care...
  6. ncbi request reprint Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation
    Corey Cutler
    Department of Medical Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 11:551-7. 2005
    ..A careful monitoring strategy for TMA should be used with a sirolimus-containing graft-versus-host disease prophylaxis regimen...
  7. pmc Costs of allogeneic hematopoietic cell transplantation with high-dose regimens
    Akiko M Saito
    Division of Medical Oncology, Dana Farber Cancer Institute, and Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Biol Blood Marrow Transplant 14:197-207. 2008
    ..If no complications occurred, the mean cost within the first year was $79,222. These results provide cost estimates for complicated and uncomplicated HDCT procedures, as well as costs for management of specific transplant complications...
  8. ncbi request reprint Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age
    Edwin P Alyea
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Blood 105:1810-4. 2005
    ..052). Our experience suggests that, in patients over age 50, NST with fludarabine and low-dose busulfan leads to an overall outcome at least as good as that following myeloablative therapy...
  9. ncbi request reprint Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens
    Corey Cutler
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 11:383-8. 2005
    ..Less toxic GVHD prophylaxis regimens without methotrexate may have a significant effect on patient quality of life, patient outcomes, and economic outcomes associated with allogeneic stem cell transplantation...
  10. ncbi request reprint Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
    Vincent T Ho
    Dana Farber Cancer Institute, 44 Binney St, D1B21, Boston, MA 02115, USA
    Blood 104:1224-6. 2004
    ..Eight of 24 patients (33%) are alive at 6.3 to 24.6 months (median, 7.2 months). Denileukin diftitox is tolerable and has promising activity in steroid-refractory acute GVHD...
  11. pmc Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission
    David B Miklos
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, M530, Boston, MA 02115, USA
    Blood 105:2973-8. 2005
    ..Antibody response to Y-chromosome encoded histocompatibility antigens (H-Y antigens) was also associated with maintenance of disease remission (P < .0001). B cells may provide a new target for immune intervention in chronic GVHD...
  12. pmc Rituximab for steroid-refractory chronic graft-versus-host disease
    Corey Cutler
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 108:756-62. 2006
    ..We conclude that specific anti-B-cell therapy with rituximab may be beneficial for patients with steroidrefractory chronic GVHD. This trial was registered at www.clinicaltrials.gov as #NCT00136396...
  13. pmc A disease risk index for patients undergoing allogeneic stem cell transplantation
    Philippe Armand
    Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA
    Blood 120:905-13. 2012
    ....
  14. ncbi request reprint Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation
    Martha Wadleigh
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Blood 102:1578-82. 2003
    ..Three of 14 patients who received GO prior to SC transplantation died of VOD. We conclude that patients undergoing SC transplantation within a short interval from GO administration are at increased risk of developing VOD...
  15. pmc Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease
    Emmanuel Zorn
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Blood 106:2903-11. 2005
    ..These findings support the development of new strategies to increase the number of Tregs following allogeneic hematopoietic stem cell transplantation to prevent or correct cGVHD...
  16. ncbi request reprint Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study
    Francisco M Marty
    Division of Infectious Diseases and Hematopoietic Stem Cell Transpalntation Service, Brigham and Women s Hospital and Dana Farber Cancer Instiute, Harvard Medical School, Boston, MA 02115, USA
    Blood 102:2768-76. 2003
    ..Pre-emptive systemic antifungal therapy against molds should be considered in patients who develop severe GVHD after HSCT if infliximab is used...
  17. ncbi request reprint Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation
    Joseph H Antin
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Blood 102:1601-5. 2003
    ..This novel agent is worthy of further study in allogeneic transplantation...
  18. ncbi request reprint Comparison of T-cell-depleted and non-T-cell-depleted unrelated donor transplantation for hematologic diseases: clinical outcomes, quality of life, and costs
    Stephanie J Lee
    Department of Adult Oncology and Department of Biostatistical Science, Dana Farber Cancer Institute, and the Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Blood 100:2697-702. 2002
    ..As prospective, randomized studies comparing methods of GVHD prophylaxis are performed, assessment of quality of life and costs should be included to fully understand the overall impact of each intervention...
  19. pmc Private cord blood banking: experiences and views of pediatric hematopoietic cell transplantation physicians
    Ian Thornley
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Pediatrics 123:1011-7. 2009
    ..Pediatric hematopoietic cell transplantation physicians are currently best situated to use cord blood therapeutically. We sought to describe the experiences and views of these physicians regarding private cord blood banking...
  20. ncbi request reprint Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation
    Joseph H Antin
    Department of Medical Oncology and Biostatistical Science, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 100:3479-82. 2002
    ..We conclude that blockade of IL-1 using IL-1Ra during conditioning and 10 days immediately after transplantation is not sufficient to reduce GVHD or toxicity or to improve survival...
  21. pmc Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis
    John Koreth
    Dana Farber Cancer Institute, D1B05, 450 Brookline Ave, Boston, MA 02215, USA
    J Clin Oncol 31:2662-70. 2013
    ..We evaluated RIC transplantation versus nontransplantation therapies in older patients with MDS stratified by International Prognostic Scoring System (IPSS) risk...
  22. ncbi request reprint Clinical evaluation of oral chronic graft-versus-host disease
    Nathaniel S Treister
    Division of Oral and Maxillofacial Surgery, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 14:110-5. 2008
    ....
  23. ncbi request reprint Physicians' attitudes about quality-of-life issues in hematopoietic stem cell transplantation
    Stephanie J Lee
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 104:2194-200. 2004
    ....
  24. pmc Donor-recipient mismatch for common gene deletion polymorphisms in graft-versus-host disease
    Steven A McCarroll
    Department of Molecular Biology, Massachusetts General Hospital, Boston, Massachusetts, USA
    Nat Genet 41:1341-4. 2009
    ..Human genome structural variation merits investigation as a potential mechanism in diseases of alloimmunity...
  25. pmc Relationship of race/ethnicity and survival after single umbilical cord blood transplantation for adults and children with leukemia and myelodysplastic syndromes
    Karen K Ballen
    Division of Hematology Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Biol Blood Marrow Transplant 18:903-12. 2012
    ..These results suggest that blacks have inferior survival to whites after single UCBT, but outcomes are improved when units with a higher cell dose are used...
  26. doi request reprint Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study
    Stephanie J Lee
    Dana Farber Cancer Institute, Boston, MA, USA
    Br J Haematol 143:511-9. 2008
    ..These results show that bortezomib was associated with significantly better multidimensional HRQL compared with dexamethasone, consistent with the better clinical outcomes seen with bortezomib...
  27. ncbi request reprint Transplantation's greatest challenges: advances in chronic graft-versus-host disease
    Warren D Shlomchik
    Department of Medical Oncology, Yale University School of Medicine, New Haven, Connecticut, USA
    Biol Blood Marrow Transplant 13:2-10. 2007
    ..In this overview, we address 3 key areas related to chronic GVHD that hold the highest promise for major advances in the near future: pathobiology, response criteria, and therapy...
  28. ncbi request reprint Advance care planning in patients undergoing hematopoietic cell transplantation
    Steven Joffe
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 13:65-73. 2007
    ..Even though ACP was more prevalent among this sample than in the general population, its use still could be enhanced, given the high risks of decisional incapacity and death that HCT patients face...
  29. pmc Bone marrow or peripheral blood for reduced-intensity conditioning unrelated donor transplantation
    Mary Eapen
    Mary Eapen, Brent R Logan, Mary M Horowitz, and Xiaobo Zhong, Medical College of Wisconsin, Milwaukee, WI Miguel Angel Perales, Memorial Sloan Kettering Cancer Center, New York, NY Stephanie J Lee, Fred Hutchinson Cancer Research Center, Seattle, WA Vanderson Rocha, Churchill Hospital, Oxford, United Kingdom Robert J Soiffer, Dana Farber Cancer Institute, Boston, MA and Richard E Champlin, MD Anderson Cancer Center, Houston, TX
    J Clin Oncol 33:364-9. 2015
    ..Because immune modulation plays a significant role in sustaining clinical remission after RIC, we hypothesize that higher graft-versus-host disease (GVHD) associated with PB transplantation may offer a survival advantage...
  30. ncbi request reprint The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera
    Ayalew Tefferi
    Division of Hematology and Laboratory Medicine, Mayo Clinic, Rochester, Minnesota 55905, and Department of Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Cancer 106:631-5. 2006
    ..Several studies have recently reported on the occurrence of a JAK2(V617F) mutation in myeloid cells from the majority of patients with polycythemia vera (PV). The clinical relevance of this novel observation currently is under study...
  31. ncbi request reprint Chronic graft-versus-host disease
    Stephanie J Lee
    Department of Adult Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 9:215-33. 2003
    ..It also provides a comprehensive listing of the published clinical trials aimed at prevention and primary treatment of chronic GVHD...
  32. pmc New approaches for preventing and treating chronic graft-versus-host disease
    Stephanie J Lee
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 105:4200-6. 2005
    ..Inherent difficulties in conducting human clinical trials also contribute to the lack of meaningful progress. This review covers potential new approaches to the prevention and treatment of chronic GVHD...
  33. pmc Biomarker Panel for Chronic Graft-Versus-Host Disease
    Jeffrey Yu
    Jeffrey Yu, Kushi Kushekhar, Mohammad Abu Zaid, and Sophie Paczesny, Indiana University School of Medicine, Indianapolis, IN Barry E Storer, Paul J Martin, Mary E Flowers, John A Hansen, Stephanie J Lee, Qing Zhang, Philip R Gafken, and Yuko Ogata, Fred Hutchinson Cancer Research Center Barry E Storer, University of Washington School of Medicine, Seattle, WA Mukta Arora, University of Minnesota, Minneapolis, MN Corey Cutler, Dana Farber Cancer Institute, Boston, MA Madan Jagasia, Vanderbilt University, Nashville, TN Joseph Pidala, H Lee Moffitt Cancer Center, Tampa, FL Betty K Hamilton, Cleveland Clinic Foundation, Cleveland, OH George L Chen, Roswell Park Cancer Institute, Buffalo, NY and Iskra Pusic, Washington University School of Medicine, St Louis, MO
    J Clin Oncol 34:2583-90. 2016
    ..To identify diagnostic and prognostic markers of chronic graft-versus-host disease (cGVHD), the major cause of morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT)...
  34. pmc Assessing the relationship between oral chronic graft-versus-host disease and global measures of quality of life
    Joseph DePalo
    Harvard School of Dental Medicine, 188 Longwood Avenue, Boston, MA 02115, USA
    Oral Oncol 51:944-9. 2015
    ..Patients with cGVHD experience reduced quality of life (QOL), yet the specific impact of oral cGVHD on QOL is poorly understood. The objective of this study was to characterize the impact of oral cGVHD on global measures of QOL...
  35. pmc Impact of age on quality of life, functional status, and survival in patients with chronic graft-versus-host disease
    Areej El-Jawahri
    Division of Bone Marrow Transplantation, Massachusetts General Hospital Cancer Center, Boston, Massachusetts Harvard Medical School, Boston, Massachusetts Electronic address
    Biol Blood Marrow Transplant 20:1341-8. 2014
    ..Therefore, we did not find evidence that older age is associated with worse outcomes in patients with moderate or severe chronic GVHD. ..
  36. ncbi request reprint Direct-to-consumer advertising in oncology: a content analysis of print media
    Gregory A Abel
    Center for Outcomes and Policy Research, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 25:1267-71. 2007
    ..Content analysis of cancer-related direct-to-consumer advertising (DTCA), with a focus on how benefit and risk/adverse effect information is presented, is essential to understanding its potential impact on oncology outcomes...
  37. ncbi request reprint Sentinel lymph node biopsy for evaluation and treatment of patients with Merkel cell carcinoma: The Dana-Farber experience and meta-analysis of the literature
    Sheela G Gupta
    Cutaneous Oncology Disease Center, Dana Farber Brigham and Women s Cancer Center, Boston, Mass, USA
    Arch Dermatol 142:685-90. 2006
    ..To determine the diagnostic accuracy and usefulness of sentinel lymph node biopsy (SLNB) and computed tomographic scans in the initial evaluation and treatment of patients with Merkel cell carcinoma (MCC)...
  38. pmc Prospective international validation of the Quality of Life in Myelodysplasia Scale (QUALMS)
    Gregory A Abel
    Division of Population Sciences, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA Center for Leukemia, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Haematologica 101:781-8. 2016
    ..81), and significant changes for patients hospitalized or with infections between administrations (both P<0.01). These data suggest the QUALMS is a valuable tool for assessing MDS-specific quality of life in the modern treatment era. ..
  39. pmc Costs of allogeneic hematopoietic cell transplantation using reduced intensity conditioning regimens
    Nandita Khera
    Division of Hematology Oncology, Mayo Clinic in Arizona, Phoenix, Arizona, USA Dana Farber Brigham and Women s Cancer Center, Boston, Massachusetts, USA Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    Oncologist 19:639-44. 2014
    ..Use of unrelated/alternative donors, transplant for diseases other than lymphoma or myeloma, and acute GVHD were predictors for higher early costs, and extensive chronic GVHD and death were associated with higher late costs. ..
  40. ncbi request reprint A survey of diagnosis, management, and grading of chronic GVHD
    Stephanie J Lee
    Center for Outcomes and Policy Research, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 8:32-9. 2002
    ..We conclude that studies defining appropriate diagnostic pathways, criteria for disease activity, and prognosis could help standardize management of cGVHD. There is an urgent need to develop and test new approaches to treat cGVHD...
  41. ncbi request reprint Patient-reported outcomes in multiple myeloma
    Stephanie J Lee
    Department of Adult Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Boston, MA, USA
    J Natl Compr Canc Netw 2:379-83. 2004
    ..In multiple myeloma, several patient-reported measures have been used to enrich our understanding of the disease's impact on patients' lives and the risks and benefits of specific treatments...
  42. ncbi request reprint Trends in survival rates after allogeneic hematopoietic stem-cell transplantation for acute and chronic leukemia by ethnicity in the United States and Canada
    Derek S Serna
    Department of Internal Medicine, Health Policy Institute, Medical College of Wisconsin Milwaukee, WI 53226, USA
    J Clin Oncol 21:3754-60. 2003
    ..Differences in survival among ethnic groups in the United States are reported in numerous diseases and treatment strategies. Whether survival after allogeneic hematopoietic stem-cell transplantation (HSCT) differs by ethnicity is uncertain...
  43. ncbi request reprint Outcomes after hematopoietic stem-cell transplantation for hematologic malignancies in patients with or without advance care planning
    Apar Kishor Ganti
    University of Nebraska Medical Center, Section of Oncology Hematology, 987680 Nebraska Medical Center, Omaha, NE 68198 7680, USA
    J Clin Oncol 25:5643-8. 2007
    ..We conducted this analysis to determine if engagement in ACP among patients who undergo HSCT is associated with adverse outcomes...
  44. ncbi request reprint High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation
    Stephanie J Lee
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 110:4576-83. 2007
    ..High-resolution DNA matching for HLA-A, -B, -C, and -DRB1 alleles is associated with higher rates of survival...
  45. pmc MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia
    Yana Pikman
    Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS Med 3:e270. 2006
    ....
  46. ncbi request reprint Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse
    Stephanie J Lee
    Graft vs Host Disease Working Committee of the International Bone Marrow Transplant Registry, Health Policy Institute, Medical College of Wisconsin, Milwaukee, WI, USA
    Blood 100:406-14. 2002
    ..Survival and disease-free survival of the most favorable cGVHD group in each scheme were similar, or better, than those of patients without cGVHD; these patients may not need aggressive or extended immune suppression...
  47. ncbi request reprint Association of depressive syndrome and early deaths among patients after stem-cell transplantation for malignant diseases
    Fausto R Loberiza
    Health Policy Institute and the Department of Medicine, Hematology and Oncology, Bone Marrow Transplantation Program, Medical College of Wisconsin, Milwaukee, WI 53224, USA
    J Clin Oncol 20:2118-26. 2002
    ..However, depression is not well studied in the setting of hematopoietic stem-cell transplantation (HSCT). We examined the association between depressive syndrome and survival after HSCT...
  48. ncbi request reprint Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Res
    J Douglas Rizzo
    Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
    Biol Blood Marrow Transplant 12:138-51. 2006
    ....
  49. pmc Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Société Française de Greffe de Moëlle et Thérapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) pros
    Jean Yves Cahn
    Department of Onco Hematology, Hopital Michallon, Centre Hospitalo Universitaire, INSERM EMI 353, 38700 Grenoble Cedex 9, France
    Blood 106:1495-500. 2005
    ..Validity of these results in populations receiving peripheral blood transplants or nonmyeloablative conditioning regimens remains to be tested...
  50. ncbi request reprint Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study
    Gorgun Akpek
    Department of Oncology, Johns Hopkins University, Baltimore, MD, USA
    Blood 102:802-9. 2003
    ..Although the new clinical grading based on the model is promising because of its utility across multiple independent data sets, prospective validation is needed...
  51. ncbi request reprint Role of skin biopsy to confirm suspected acute graft-vs-host disease: results of decision analysis
    Bahar F Firoz
    Department of Dermatology, New York University, New York, USA
    Arch Dermatol 142:175-82. 2006
    ..To estimate the value of skin biopsy in the evaluation of suspected acute cutaneous graft-vs-host disease (GVHD) after allogeneic stem cell transplantation...
  52. ncbi request reprint Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report
    Howard M Shulman
    Department of Pathology, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, University of Washington School of Medicine, Seattle, Washington 98109, USA
    Biol Blood Marrow Transplant 12:31-47. 2006
    ..Consensus recommendations and suggested data-capture forms should be validated in prospective clinicopathologic studies...
  53. pmc Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia
    Stephanie J Lee
    Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Blood 112:3500-7. 2008
    ..Acute graft-versus-host disease rates were similar between IM(+) and IM(-) groups regardless of leukemia phase. These results should be reassuring to patients receiving IM before HCT...
  54. ncbi request reprint National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report
    Alexandra H Filipovich
    Cincinnati Children s Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio 45229, USA
    Biol Blood Marrow Transplant 11:945-56. 2005
    ..It is currently recommended that systemic therapy be considered for patients who meet criteria for chronic GVHD of moderate to severe global severity...
  55. ncbi request reprint Differences in characteristics of US hematopoietic stem cell transplantation centers by proportion of racial or ethnic minorities
    Christopher J Schwake
    Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
    Biol Blood Marrow Transplant 11:988-98. 2005
    ..Our results suggest that the inferior survival reported in ethnic minorities after HSCT may not be readily explained by center effects...
  56. ncbi request reprint Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report
    Kirk R Schultz
    British Columbia Children s Hospital, University of British Columbia, Vancouver, British Columbia, Canada
    Biol Blood Marrow Transplant 12:126-37. 2006
    ..Both approaches have merit and should be pursued. The consistent treatment and standardized documentation needed to support biomarker studies are most likely to be satisfied in prospective clinical trials...
  57. ncbi request reprint Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report
    Steven Z Pavletic
    National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1203, USA
    Biol Blood Marrow Transplant 12:252-66. 2006
    ..The proposed response criteria are based on current expert consensus opinion and are intended to improve consistency in the conduct and reporting of chronic GVHD trials, but their use remains to be demonstrated in practice...
  58. ncbi request reprint Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working
    Daniel Couriel
    University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Biol Blood Marrow Transplant 12:375-96. 2006
    ..Optimal care of patients with chronic GVHD often requires a multidisciplinary approach...
  59. ncbi request reprint Association of transplant center and physician factors on mortality after hematopoietic stem cell transplantation in the United States
    Fausto R Loberiza
    University of Nebraska Medical Center, Center for International Blood and Marrow Transplant Research CIBMTR, Medical College of Wisconsin, Milwaukee, WI, USA
    Blood 105:2979-87. 2005
    ..Greater physician involvement in patient care is important in producing favorable outcomes after HSCT. To more clearly establish the role of the factors we identified, further studies are recommended...
  60. ncbi request reprint National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report
    Paul J Martin
    Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, Washington 98109 1024, USA, and Hopital St Louis, Paris, France
    Biol Blood Marrow Transplant 12:491-505. 2006
    ..The use of consistent standards in clinical trial designs to evaluate agents that have activity in pathogenic pathways could facilitate advances in the treatment of chronic GVHD...
  61. ncbi request reprint End points to establish the efficacy of new agents in the treatment of acute leukemia
    Frederick R Appelbaum
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 109:1810-6. 2007
    ..In this report, we present the results of that effort...
  62. ncbi request reprint Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia
    Sergio A Giralt
    M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77230, USA
    Br J Haematol 137:461-7. 2007
    ..Most patients now receive a trial of imatinib before proceeding to HCT...
  63. ncbi request reprint A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome
    Corey S Cutler
    International Bone Marrow Transplant Registry, Medical College of Wisconsin, 8701 Watertown Plank Rd, PO Box 26509, Milwaukee, WI 53226, USA
    Blood 104:579-85. 2004
    ..For low- and intermediate-1-risk MDS, delayed BMT is associated with maximal life expectancy, whereas immediate transplantation for intermediate-2- and high-risk disease is associated with maximal life expectancy...
  64. pmc Chronic Graft-versus-Host Disease--implementation of the National Institutes of Health Consensus Criteria for Clinical Trials
    Linda M Griffith
    Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Biol Blood Marrow Transplant 14:379-84. 2008
  65. ncbi request reprint JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance
    Alexandra P Wolanskyj
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Br J Haematol 131:208-13. 2005
    ..Therefore, although the presence of JAK2(V617F) in ET appears to promote a PV phenotype, it might not carry treatment-relevant information...